Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
60 Degrees Pharma (SXTP) announces a $1.043M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
-
60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.
-
60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.
-
60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.
-
60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs.
-
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
-
60 Degrees Pharmaceuticals launches a pilot to boost ARAKODA® awareness, focusing on virtual sales and a co-pay program for malaria prevention.
-
60 Degrees Pharmaceuticals closes a $4M private placement for working capital and R&D, with stock and warrants priced at $1.38 per share.
-
60 Degrees Pharmaceuticals raises $4M through private placement for working capital, commercialization, and R&D, with H.C. Wainwright as placement agent.
-
60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days.